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Abstract
Background: Lymphatic filariasis (LF) is a major public health problem in the Pacific Region, including in Fiji.
Through transmission by the mosquito vector Aedes, Fiji has suffered the burden of remaining endemic with LF
despite efforts at elimination prior to 1999. In the year 1999, Fiji agreed to take part in the Pacific Programme for
Elimination of LF (PacELF) and the Global Programme to Eliminate LF.
Methods: This study reviewed and collated past data on LF in Fiji between 1997 and 2007. Sources included
published papers as well as unpublished PacELF and WHO program meeting and survey reports. Records were held
at Fiji’s Department of Health and Medical Services, James Cook University and the WHO office in Suva, Fiji.
Results: Baseline surveys between 1997 and 2002 showed that Fiji was highly endemic for LF with an estimated
16.6% of the population antigen positive and 6.3% microfilaria positive at that time. Five rounds of annual mass
drug administration (MDA) using albendazole and diethylcarbamazine commenced in 2002. Programmatic
coverage reported was 58–70% per year, but an independent coverage survey in 2006 in Northern Division after
the fifth MDA suggested that actual coverage may have been higher. Monitoring of the program consisted of
antigen prevalence surveys in all ages with sentinel and spot check surveys carried out in 2002 (pre MDA), 2004,
and 2005, together with knowledge, attitude, and practice surveys. The stop-MDA survey (C survey) in 2007 was a
nationwide stratified cluster survey of all ages according to PacELF guidelines, designed to sample by administrative
division to identify areas still needing MDA. The national antigen prevalence in 2007 was reduced by more than a
third to 9.5%, ranging from 0.9% in Western Division to 15.4% in Eastern Division, while microfilaria prevalence was
reduced by almost four-fifths to 1.4%. Having not reached the target threshold of 1% prevalence in all ages, Fiji
wisely decided to continue MDA after 2007 but to move from nationwide implementation to four (later five)
separate evaluation units with independent timelines using global guidelines, building on program experience to
put more emphasis on increasing coverage through prioritized communication strategies, community participation,
and morbidity alleviation.
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Conclusion: Fiji conducted nationwide MDA for LF annually between 2002 and 2006, monitored by extensive
surveys of prevalence, knowledge, and coverage. From a high baseline prevalence in all divisions, large reductions
in overall and age-specific prevalence were achieved, especially in the prevalence of microfilariae, but the threshold
for stopping MDA was not reached. Fiji has a large rural and geographically widespread population, program
management was not consistent over this period, and coverage achieved was likely not optimal in all areas. After
learning from these many challenges and activities, Fiji was able to build on the progress achieved and the
heterogeneity observed in prevalence to realign towards a more stratified and improved program after 2007. The
information presented here will assist the country to progress towards validating elimination in subsequent years.
Keywords: Lymphatic filariasis, Fiji, Parasitic disease, Vector, Elimination, PacELF
Background
Lymphatic filariasis (LF) is a parasitic disease of humans,
transmitted through a mosquito vector carrying the
pathogenic worm. It can take 5–10 years for initial
symptoms to occur [1]. The delayed onset of LF symp-
toms is one of the reasons that it has been able to reach
endemic proportions in so many countries, as unsus-
pecting infected persons spread the parasite when a
mosquito transfers it from one infected person to the
next. Other reasons include lack of resources or
prioritization of the disease and neglect of those suffer-
ing [2]. Although LF does not directly lead to death, it
can cause severe chronic disability, including limb and
scrotal swelling [3]. Three species of parasitic worms
exist worldwide: Wuchereria bancrofti, Brugia malayi,
and B. timori, which are transmitted via a number of
mosquito genera including Anopheles, Aedes, Culex, and
Mansonia [4].
Global Programme to Eliminate LF
In 1997, the World Health Assembly resolved to elimin-
ate LF as a public health problem [5] through use of
mass drug administration (MDA) using a single annual
dose of deworming drugs for a period of 4–6 years to re-
duce blood microfilariae (Mf) in LF-affected patients and
block transmission. The program also aimed to reduce
and prevent the morbidity and disability that occurs in
chronic LF [6, 7], including reducing the number of
acute dermatolymphangioadenitis attacks. By 2014, the
GPELF had greatly reduced the estimated number of
cases worldwide, but there were still an estimated 68
million persons affected by LF, with 36 million microfi-
laraemic persons, 19 million hydrocoele cases, and 17
million lymphedema cases [8].
Pacific Programme to Eliminate LF
The Pacific Programme to Eliminate LF (PacELF) pro-
gram was launched under the auspices of WHO, the
Secretariat of the Pacific Community (SPC), and donor
agencies in 1999 [9]. At that time, 16 of the 22 countries
and territories in the Pacific Region (including Fiji) were
classified as endemic by the criterion of LF population
prevalence of > 1% in any part of the country [10].
Under PacELF guidelines, target dates were recom-
mended for surveillance milestones to monitor program
implementation and provide support as needed. The
baseline survey before the start of MDA, also known as
A survey, used rapid immunochromatographic tests
(ICT) to determine antigen prevalence. During the MDA
rounds, sentinel site surveys referred to as the B surveys,
monitored program progress. After the fifth round of
MDA, a nationwide antigen survey in all ages (the C sur-
vey) was scheduled to determine whether LF prevalence
was low enough for the MDA to be stopped [9]. Once
that milestone was reached, PacELF guidelines called for
a D survey at least 2 years later in 5-year-old children to
confirm interruption of transmission. The PacELF C and
D surveys have now been replaced by current global
guidelines which call for a stop-MDA survey and two
further post-MDA transmission assessment surveys
(TAS) in 6–7-year olds at 2–3-year intervals, before the
program can be “validated” as having achieved elimin-
ation of LF as a public health problem [11, 12].
The Fiji islands
Fiji is a group of more than 300 islands spanning 18,000
km2 of the Pacific Ocean (Fig. 1). There are four divi-
sions and 15 subdivisions, also known as provinces. The
capital is Suva, in the Central Division. Fiji was home to
an estimated 837,271 people in 2007 which has grown to
884,887 by the 2017 census [13]. The population in 2007
was 56.8% ethnic Fijians (iTaukei), 37.5% Indian, 5.6%
Chinese, 3.5% European, 1.8% other Pacific Islanders,
1.2% Rotuman, and 1.7% mixed or other. The median
age in 2017 was 27.5 years and 55.9% of the population
live in urban areas, an increase from 50.7% in 2007.
Lymphatic filariasis in Fiji
In Fiji, W. bancrofti is transmitted predominantly by
highly efficient Aedes vectors [9]. The known mosquito
vector species are Ae polynesiensis, Ae pseudoscutellaris,
Ae horrescens, Ae rotumae, and Ae fijiensis. Fiji has a
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history of being highly endemic for W. bancrofti LF,
which was described there as early as 1876 [14, 15].
The first attempt to eliminate LF in Fiji was in 1944
through a mass vector control scheme with the aim of
eliminating mosquito breeding sites, or through use of in-
secticides such as dichloro-diphenyltrichloroethane
(DDT) [9]. In the late 1940s and early 1950s, there was ex-
perimental use of diethylcarbamazine (DEC) [16], but the
first full scale MDA in Fiji started in 1958 [17] in a popu-
lation of around 1500 people in Rewa district near Suva
(see Fig. 1). An Mf prevalence of 12.2% (N = 1200) was
found prior to the 1958 MDA, which consisted of 6
weekly doses of 6mg/kg. The second course of 6 weekly
doses was given 6 months later in early 1959, and 6
months after that the Mf prevalence in the study area was
2.7% (N = 1123). Subsequent testing in the years after
MDA showed a rise in Mf prevalence, and in 1963, the Mf
prevalence in the study area was 5.5% (N = 1430) [18].
Ministry of Health pre-MDA surveys conducted
throughout Fiji starting in 1968 are summarized in the
PacELF Way book [9]. Testing in 1969 on Taveuni and
Koro islands revealed an Mf prevalence of 23% (N =
947), while in Vanua Levu, it was 13% (N = 3538). An
MDA starting in 1969 in Fiji [19] once again attempted
to control LF using 5 mg/kg of DEC weekly for 6 weeks,
followed by treatment with the same dose on a monthly
basis over 22 months. This MDA was carried out across
the entirety of Fiji for a 2-year cycle in five stages and
was completed in 1975, resulting in Mf prevalence in all
treated areas decreasing to 1% or less [20, 21].
A mass Mf survey in 1983–1984 in the remote Fijian
islands of Lau (N = 2329) and Rotuma (N = 1689) found
that there was still high endemicity, since the prevalence
of Mf was 7.9% and 21.2% respectively [15]. This appar-
ent resurgence of LF led to the Filariasis Control Pilot
Project in Fiji between 1984 and 1991 in three areas
(Kadavu, Lomaiviti, and Rotuma). One area was admin-
istered DEC at 6mg/kg annually for 5 years, the second
was administered DEC at 5mg/kg weekly for 6 weeks,
then the same dose monthly for the following 22months,
Fig. 1 Map of Fiji with division and subdivision (province) boundaries. Source: Fraenkel (2015) Journal of Pacific History 2015 DOI: 10.1080/
00223344.2015.1013598, with permission. Map produced by CartoGIS Services, ANU College of Asia and the Pacific, Australian National University
(reproduced with permission)
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and the third area did not have DEC administered for the
initial 3-year period [15]. Results of the Filariasis Control
Pilot Project saw the first two regions having marked re-
duction of Mf prevalence. Important research demonstrat-
ing the efficacy of LF annual single dose was carried out
on Kadavu island during 1985–1990 [22]. Apart from
some trials of DEC and ivermectin in Eastern Division in
1996 [9], no further MDA efforts were conducted until
the start of PacELF in 1999.
Regarding morbidity, a survey carried out between
1991 and 1995 assessed 18,253 people (probably adults,
but of unknown age) and found that 2733 were affected
by advanced stage LF lymphedema and/or hydrocele (re-
ported in [23]). Estimates based upon the above survey
suggest the LF morbidity prevalence in adults at that
time could have been as high as 17% [23]. However, the
method or location of sampling in these surveys is not
known, so these results should be considered of un-
known accuracy; no further information on morbidity
during the time period of this study is available.
A cross-cultural comparison of how LF affects Fiji’s
population found that iTaukei had higher LF prevalence
than Indo-Fijians. This may be because ethnicity influ-
ences the degree of exposure to mosquitoes, with indi-
genous Fijians being more likely to work in agricultural
disciplines and live in more remote areas [24].
In 1999, Fiji recommitted to elimination of LF with
the support of PacELF following the strategies described
above. This paper reviews the activities and surveys
conducted until 2007. During this period, there was 5
years of MDA, a vector control evaluation, knowledge-
attitude-practice surveys, baseline and sentinel site sur-
veys, a representative large C survey, and a MDA cover-
age survey [25, 26]. Fiji continued MDA after 2007, and
the post-MDA surveillance period and TAS survey re-
sults will be reported separately.
Methods
This data included in this paper were collected from
published and unpublished reports and data from
PacELF and Fiji Ministry of Health and Medical Services
(MOHMS) databases relevant to PacELF in Fiji between
the years of 1997 and 2007. Records of all sites surveyed
(number tested and number positive by ICT or Mf blood
slide) and the MDA coverage were extracted from
PacELF databooks in 2003 and 2006 [25, 26] and the
PacELF book [9]. Documents held at the JCU WHO
Collaborating Centre PacELF Warehouse (jcu.edu.au/
pacelf) were searched.
All data in this paper were collected and reported
under PacELF or Fiji MOHMS supervision. Reports on
events occurring in Fiji that noted obstacles, successes,
and plan variations to the PacELF guidelines specifically
for Fiji have been used to create an overview of Fiji’s
PacELF progress. This paper will discuss Fiji’s PacELF
journey, as well as the successes and challenges Fiji has
undergone in efforts to eliminate LF during the years
1997 to 2007.
Antigen prevalence was the main method used to de-
termine positive LF infection in the surveys reported.
Microfilaria prevalence was also determined in some
surveys using finger prick blood slides collected from
those who were antigen positive, stained, and read ac-
cording to WHO guidelines [11].
Results
Program overview
A timeline of activities is shown in Table 1, which out-
lines survey events and MDA implemented. Mapping
(A) surveys using ICT antigen tests to determine base-
line endemicity were underway in Fiji starting in 1997,
and provided data for determining that MDA was
needed everywhere in the country.
In the second half of the year 2000, a draft National
Plan of Action for LF elimination was finalized, a Na-
tional Committee for LF Elimination in Fiji was estab-
lished and a National Policy for the Filariasis campaign
was created. December 2000 saw awareness workshops
in all of Fiji’s division communities and memos sent to
the public about further blood surveillance that com-
menced in January 2001 [9]. The PacELF plan of action
for Fiji saw MDA as the primary intervention. It was to
be carried out on all islands for the entire population,
with the only participant exclusions being children
under 24 months, pregnant women and people consid-
ered to be extremely sick (hospitalized, on dialysis or
with cancer). Vector control appropriate to the environ-
ment was recommended in conjunction with MDA, and
clinical management to relieve symptoms and prevent




The drugs DEC and albendazole were the official MDA
treatments and were administered by age group based
upon assumed weight and age [27] (Table 2).
Exclusion criteria of MDA treatment:
a. Sick individuals who are unable to take medications
b. Children less than 2 years of age unable to take
medication
c. Pregnant women (however, postpartum lactating
women will not be excluded)
MDA delivery strategies
The first MDA protocol involved door-to-door delivery
of the MDA drugs albendazole and DEC. Initially, there
Manolas et al. Tropical Medicine and Health           (2020) 48:88 Page 4 of 12
was shortage of both human and financial resources for
the 3–4-month period, especially in transporting persons
to remote villages. In the second through to the fifth
rounds of MDA, the protocol changed, so people were
expected to go to a pick-up point over a certain weekend,
where a health worker would provide the DEC and alben-
dazole to be taken later at home. Prior to the weekend
that the MDA was delivered, there was a mass MDA pro-
motion campaign in urban regions and villages involving
public figures and a range of media so people would be
encouraged and prepared to take part in MDA [9]. Details
of the usual MDA strategy are described in [27].
MDA coverage
Table 3 shows the percentage of population estimated to
have taken part in the MDA program, as determined
from programmatic records and the estimated census
population.
MDA coverage survey
An independent coverage survey was conducted by lot
quality assurance sampling in 2006 after the fifth MDA.
It included all 4 subdivisions and 19 medical areas in the
Northern region [29]. Each medical area was regarded as
a “lot” except in large medical areas where nursing zone
was considered a lot. A total of 27 lots was selected out
of a possible 38 by population proportionate sampling.
Villages were selected at random from a list and 13
households were selected in each village. The sample
Table 1 Timeline of PacELF events, surveys, and MDA in Fiji 1997–2007
Year Events Surveys MDA
1997 Baseline (A) surveys 1997–2001:
Rotuma (N = 97)
1998
1999
2000 National Plan of Action finalized.
National Committee formed.
National Policy developed.
Nationwide education and awareness campaign on MDA and LF.
Baseline (A) survey 1997–2001 continued:
Mapping survey (by ICT) to confirm endemic LF status in Fiji
and the need for MDA: convenience sampling of 5893 people
in > 45 sites across Fiji
2001 July 2001—PacELF home office established at the Fiji Centre for
Communicable Disease Control in Tamavua
2002 Public health nurses trained; health promotion material distributed
and campaign for MDA underway
Continued village surveys pre-MDA: convenience testing (by
ICT and Mf) in 3214 persons of all ages in 48 villages. All
positive cases were treated.
MDA1
2003 Full-time PacELF coordinator is established. Knowledge, attitudes,
and practices (KAP) questionnaire administered by health
professionals to MDA participants over 16.
Follow-up testing and treatment of positive cases. MDA2
2004 MDA promotional material distribution. Sentinel site (B) and spot check surveys: convenience testing
(by ICT) in persons of all ages, in 14 villages; all positive cases
treated.
MDA3
2005 Advocacy and awareness campaign managed by specially
appointed awareness committee.
Bednet study in Rewa district.
Knowledge, attitudes, and practices (KAP) questionnaire
administered by health professionals to MDA participants
over 16.
Commencement of radio and television MDA promotional
broadcasts in Fijian, Hindi, and English.
Sentinel site (B) and spot check surveys: convenience testing
(by ICT) in persons of all ages in 46 villages; all positive cases
treated.
MDA4
2006 Global Alliance meeting in Fiji—Theme of “Global Elimination
of LF: Successes and Challenges.”
Program review including review of the MDA coverage results
and communication strategy.
Follow-up: testing (by ICT) and treatment of positive cases.
Coverage survey administered in Northern Division to assess
MDA 5.
MDA5
2007 For the purpose of future LF elimination planning, identifying
at-risk areas and presenting data, Fiji program is reorganized
into 4 divisions—Eastern, Northern, Western, and Central.
Stop-MDA survey: ICT and Mf of all ages (C Survey) in 6745
people in 65 villages. Results > 1% positive in all but Western
Division.
No MDA
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size was 2162 (1042 female, 1119 male, and one un-
known); iTaukei Fijians were overrepresented due to in-
complete listings for Indo-Fijian settlements. Persons of
all ages in selected households were interviewed. Overall,
97.5% of eligible participants reported receiving the tab-
lets and of those 96.8% reported taking the tablets. This
is much higher than the program reported coverage.
The reasons for this are not clear but have been attrib-
uted by the program to either social desirability bias in
the survey, lack of recall, inaccurate registration or
population overestimate, or a combination of these
factors.
In program reports [27, 29], insufficient coverage in
some divisions was attributed to incomplete drug distri-
bution, lack of cooperation between village headmen
and health workers, side effect fears, lack of transport of
nurses to remote villages, inadequate promotion of the
MDA program, size of the village, and the ability of the
health workers to cover the area in the timeframe. Dis-
tribution of tablets at central points meant that it was
unknown whether people actually took the tablets once
they left the pick-up point. In contrast, there were high
coverage reports in some divisions that were attributed
to accessible transport for nurses, high level of commu-
nity cooperation, awareness of public on MDA benefits
and LF pathology, and active involvement of village
headmen and health workers. Health workers distribut-
ing MDA were found to be the most important informa-
tional source about LF and MDA benefits. It was
additionally noted that a shorter period of MDA distri-
bution produced a higher coverage.
Surveillance, monitoring, and evaluation of LF infection
Surveys
Baseline survey/A-survey A summary of the baseline
surveys done by subdivision in at least 45 sites between
1997 and 2001 is shown in Table S1. A total of 9350
people were tested. No Mf slides were done in these sur-
veys. Detailed results by subdivision and village (where
available) are shown in Table S1 in additional material.
Results by division and overall are given in Table 4.
The baseline survey results showed that 16.6% of the
5983 people tested had a positive ICT result. However,
the selection of the survey sites was not fully representa-
tive. Based on the results, the whole country was regarded
as one implementation unit for nationwide MDA.
Mid-term/B-surveys
For monitoring the program, sentinel sites were selected
in most subdivisions and sampled (B surveys) on two or
three occasions, starting in 2002 (before the first MDA)
and continuing in 2004 (after second MDA) and 2005
(after third MDA). Some additional sites were also sam-
pled only once during this period. Full results of baseline
and sentinel site surveys by subdivision are shown in
Table S1, and results by site for those sites that were
tested more than once in Table S2. Villages in Rewa sub-
division (Central Division) were sampled extensively for
a mosquito net project. The supplementary files demon-
strate the extreme geographic heterogeneity observed in
LF prevalence between village sites in Fiji.
The positive ICT percentage results of sites tested ac-
cording to division and subdivision are shown in Table 5.
Table 6 displays the positive Mf percentage results of pop-
ulations tested according to division and subdivision. In-
cluded in these tables are the data for subdivisions which
reported data for two or more years. Blank spaces in Ta-
bles 5 and 6 indicate no data were available for that year.
The extreme range in prevalence and persistence in some
areas to 2005 can be seen even at subdivision level, with
Rotuma and Lau islands remaining at above 30% preva-
lence even after several rounds of MDA.
Stop-MDA survey/C-survey
In 2007, the stop-MDA survey was completed via ICT
testing in nationwide clusters (villages) which were se-
lected at random from village lists. It included 65 village
sites selected from the four divisions; there were up to 8
sites per division with the exception of Rotuma island in
which 17 sites were sampled.
Results are reported according to the four divisions
within Fiji, which can be seen in Fig. 1, as well as report-
ing an overall national result. Results of the stop-MDA
survey showed that on a national scale, 9.5% of persons
tested were still positive, i.e., still well above the
Table 3 Programmatic MDA coverage in Fiji by year
2002, MDA1 2003, MDA2 2004, MDA3 2005, MDA4 2006, MDA5
Population 841,500 841,500 841,500 841,500 849,361
Registered population of all IUs 755,077 776,173 776,163 841,500 831,263
Reported number of people treated 545,780 483,983 537,484 529,615 482,383
Programmatic coverage % 70.4% 62.4% 69.2% 62.9% 58.0%
Epidemiological coverage % 64.9% 57.5% 63.9% 62.9% 56.8%
Source: [28] PCT databank
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threshold of > 1% (Table 4). By division, the Northern,
Eastern, and Central Divisions reported ICT prevalence
> 1% (Table 4 and Fig. 2). The Western Division was the
only region that “passed” the C survey with a 0.9% ICT
prevalence, but the 95% CI was above 1%.
In Fig. 2, the antigen surveys done in 1997–2001 and
in 2002 have been combined for the “pre MDA” baseline
level, in order to increase the representativeness of the
baseline in all divisions. The baseline Mf estimate is
from 2002 only. Prevalence of positive ICT declined
from the initial baseline survey result in all divisions.
The decline was shallowest in Western Division which
had the lowest baseline prevalence.
Age-specific antigen prevalence nationwide also de-
clined markedly between 1997–2001 and 2007 (Fig. 3),
but was still above 20% in males over 50 years in 2007.
Although the survey was not powered to estimate preva-
lence in particular age groups, nevertheless the presence
of 5% of children under 10 (N = 1341 tested) who were
antigen positive in 2007 suggests that transmission was
Table 4 LF prevalence in Fiji by division (positive ICT %)
Year(s) Sampling method Sample size Division No. sites Antigen positive (ICT) % Mf positive %
1997–2001 (A survey) Convenience cluster 1443 Northern 3 14.8
307 Central 5* 42.0
2616 Eastern 24 20.2
1617 Western 13 7.7
5983 All Fiji 45 16.6
2002 (pre-MDA survey) Convenience cluster 0 Northern
1807 Central 25 13.9 8.1
891 Eastern 15 23.9 6.8
583 Western 8 2.1 0.2
3281 All Fiji 48 14.5 6.3
2007 (C survey) Stratified random cluster 894 Northern 8 3.0
1431 Central 12 15.4
3541 Eastern 37 11.1
879 Western 8 0.9
6745 All Fiji 65 9.5 1.4
*All on Beqa island, a suspected hotspot
Sources: PacELF databooks 2003 and 2006 [25, 26], The PacELF way [9], WHO Fiji office records
Table 5 Baseline and sentinel site surveys: antigen positive results by division and subdivision
Division Subdivision 1997–2001 2002 2004 2005
No.
sites
N tested Ag pos % No.
sites
N tested Ag pos % No.
sites
N tested Ag pos % No.
sites
N tested Ag pos %
Northern Bua 1* 512 14.3
Cakaudrove 1 491 27.7 1 57 33.3
Macuata 1 440 0.9
Central Naitasiri 4 248 26.2 1 97 26.8
Rewa 21 1559 11.9 6 302 26.2 30 2619 6.3
Serua/Namosi 5 307 42.0 4 233 27.0 5 410 14.9
Eastern Kadavu 7 602 12.1 1 166 16.3
Lau 12 1300 21.5 15 891 23.9 3 234 31.2
Lomaiviti 1 551 11.6
Rotuma 4 163 67.5 4 176 35.8
Western Ba 12 582 5.7 8 583 2.1 4 132 7.6 1 64 0.0
Nadroga-Navosa 1 525 0.2
Ra 1 510 17.7
*Lack of certainty on number of sites
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still ongoing. Overall, the number of persons with
known age and gender in the 2007 survey was 6540 out
of 6745 tested.
As a result of the stop-MDA surveillance outcomes,
Fiji was deemed not to be ready to terminate MDA and
commence post-MDA surveillance, therefore continuing
into its 6th round of MDA in 2008 after interruption of
MDAs in 2007.
Vector control
Vector control is also a recommended LF control strat-
egy in Fiji as in all PacELF countries [9, 30], with the
aim to reduce transmission between infected and unin-
fected persons. However, some species like Ae.polyne-
siensis may be difficult to control because of their
extensive and unreachable natural habitats.
Table 6 sentinel site survey Mf results by division and subdivision
Division Subdivision 1997-2001 2002 2004 2005
Mf not done No sites N slides Mf pos % No. sites N slides Mf pos % No sites N slides Mf pos %
Northern Bua
Cakaudrove 1 57 3.5
Macuata
Central Naitasiri 4 248 9.3 1 97 3.1
Rewa 21 1559 7.9 4 288 6.9 30 2619 2.4
Serua/Namosi 4 231 6.5 5 410 2.9
Eastern Kadavu 1 166 3.6
Lau 15 824 6.8 3 234 12.8
Lomaiviti
Rotuma 4 176 10.8
Western Ba 8 583 0.2 112 0.0 1 64 0.0
Nadroga-Navosa
Ra
Fig. 2 Prevalence of antigen and Mf positives before and after 5
rounds of MDA. Note: nationwide ICT prevalence before MDA is average
of all antigen prevalence results in 1997–2001 and 2002. Northern
Province was not surveyed in 2002. Mf prevalence data are only available
for 2002 (excludes Northern Province) and 2007. See Table 4
Fig. 3 Age- and gender-specific prevalence of antigen in 1997–2001
A survey and 2007 C survey
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Recommendations include larval habitat reduction,
insecticide-impregnated bed nets and curtains, and use
of repellent and mosquito coils [30]. A large study was
done in 2003–2004 in Rewa district (near Suva in Cen-
tral Division, see Fig. 1) to investigate whether use of
long lasting insecticidal nets (LLIN) had any impact on
LF prevalence, but the results did not find any significant
effect [31]. This may not be surprising given that the
main vectors are day-biting. Overall, prevention through
vector control (e.g., removal of larval habitats) was ap-
parently not a heavily emphasized part of the Fiji pro-
gram (or at least there is no evidence of the extent to
which it was done). Concurrently, mosquito control for
dengue vectors (transmitted by Ae aegypti and Ae albo-
pictus as well as Ae polynesiensis and the other LF vec-
tors mentioned above) was also recommended and
practiced in Fiji [32]. Methods included focal fogging
with malathion, peri-domestic focal spraying with Aqua
Resigen (bio-allethrin, permethrin, and piperonyl butox-
ide), larviciding with temephos, promotion of personal
protection from bites, and larval habitat reduction
(“clean-up campaigns”). These interventions were mainly
done in urban areas, and their extent and timing is not
known.
Knowledge of filariasis and communication strategies
A knowledge, attitudes, and practices (KAP) feedback
questionnaire was administered verbally to persons over
16 by trained health care workers in 2003, and allowed
program staff to find weaknesses in knowledge and atti-
tudes towards MDA and LF. KAP surveys were also car-
ried out in 2005 and 2006 to investigate knowledge and
inform strategies for increasing MDA participation.
The baseline KAP survey showed that the level of
knowledge of filariasis was quite high, even before
PacELF [9]. In 2003, two-thirds of the respondents said
that mosquitoes transmitted LF, although 7.5% thought
that “drinking dirty water” was the cause; responses such
as “person to person contact” and “hygiene” were each
given by less than 5% of the persons asked. More than half
(57%) of people knew that taking medicine could prevent
the spread of disease, and a further 32% mentioned mos-
quito control methods or nets for prevention [9].
Advocacy during the first two MDAs focused on
printed materials. In the 2003 survey, most participants
did not identify the printed materials as a source of in-
formation [27]. The program shifted more towards mass
media (radio and TV) in all three vernaculars. In 2005, a
KAP study was done in Rewa subdivision, and results
showed increases in knowledge about the disease as well
as awareness of the program [9]. For example, the pro-
portion of people who knew that mosquitoes transmitted
LF increased to 82%. Even though the proportion of
people knowing that taking medicine could prevent LF
remained relatively stable at 60%, a high proportion of
89% said they had taken the tablets at some time in the
past. The main reason given for not taking the drugs was
either missing or not knowing about the distribution [9].
In 2006, KAP questions were asked in conjunction
with the coverage survey in Northern Division; 73.5% of
578 respondents knew that LF is transmitted by mosqui-
toes; 60% mentioned it was a cause of elephantiasis but
only 20% considered it was a cause of hydrocoele [29].
The findings of the 2006 survey were used to develop
and test an improved health promotion strategy with
commercial media company input.
Discussion
In Fiji, prevalence of LF was very high before the start of
the PacELF MDA program, despite several previous at-
tempts at widespread MDA [9]. A steep and successful
decline in antigen prevalence was achieved between two
nationwide surveys: the baseline survey (A Survey) in
1997 to 2002 (pre-MDA), and the results of the stop-
MDA (C survey) in 2007. Antigen prevalence declined
across all divisions and can likely be attributed to MDA
and the supportive activities described in Table 1. De-
cline was observed both in overall and age-specific
prevalence of antigen, and was more marked for Mf
prevalence. However, the threshold for stopping MDA
was not reached. Vector control (including that done for
dengue control) may have contributed to the decline,
but it is not possible to tell due to lack of information
on this intervention.
Survey methodology improved over the time period
described. Initial surveys in 1997–2002 (A surveys) used
convenience sampling and were biased towards areas
likely to have LF, in order to make sure that no endemic
areas were missed. Participants in surveys consisted of
those who chose to attend. The sentinel site B surveys
were also purposively sampled and their sampling was
not uniform, with a large number of sites sampled in
Central Division, but by the 2007 stop-MDA C survey,
clusters were selected randomly and generally in propor-
tion to the population in each division. All surveys up to
2007 involved persons of all ages, which enabled the de-
cline in age-specific prevalence in all ages to be demon-
strated, although antigen prevalence over 20% persisted
in males over 50 years.
There was large variation in prevalence between divi-
sions, and decline in antigen prevalence was steepest in
regions that started with higher prevalence. The results
showed the importance of stratification for future pro-
gram activities. Relying on a national average would
mean that some areas would be undergoing unnecessary
MDA, while other regions would stop MDA too early,
allowing for a high-risk transmission environment to re-
main and lead to resurgence of LF. The sentinel site
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results show clearly the variation in prevalence and
presence of hotspots within divisions and subdivisions
as well.
Fiji was not able to reach the MDA coverage target
(80% of the eligible population) according to the guide-
lines in place during 2002–2006 [9]. The current GPELF
target of 65% of the total population [11] in all years was
also not reached, according to the programmatic coverage
reported. The nature of Fiji’s geography—multiple island
populations and many remote areas—may have affected
delivery of services and resources, including accuracy and
completeness of the MDA registers, although there was
also an indication from KAP surveys that coverage was
not optimal in urban areas. The independent coverage
survey in Northern Division in 2006 after the fifth MDA
suggested that coverage may actually have been higher
than programmatically reported, at least in some areas.
Findings of the repeated KAP surveys allowed staff to
adjust promotion and education accordingly to maximize
participation. Health promotion shifted to increase in
urban settings as a result of the KAP feedback identifying
a deficiency in this area. The renewed focus on addressing
morbidity (both in terms of assessing the burden and
addressing it) was also a major feature of the program
after 2007 [33–35].
The extensive and well-sampled C survey showing the
variation in prevalence by division enabled informed de-
cisions to be taken on how to move forward. Despite the
Western Division’s success in the stop-MDA survey, the
decision was made by the WPRO regional program re-
view group in 2008 [33] that all divisions in Fiji should
continue with MDA, but that each division would be
regarded as a separate implementation and evaluation
unit with distinct timelines for post-MDA surveillance.
Future of LF in Fiji
Fiji has had a challenging battle with LF, with many ob-
stacles to overcome in order to effectively achieve the
program goals, such as historically high prevalence, wide
geographical population distribution, and funding. Look-
ing back at program reports [33, 34], the standout chal-
lenge seemed to be MDA coverage and compliance. A
study done in Central Division in Fiji in 2010 observed
that participation in traditional village forums in Fiji was
related to taking roles in community activities for MDA
and associated with adherence to MDA regimen regard-
less of age, gender, and the educational attainment of
the individual residents [36]. Looking forward, any
future promotion endeavors required for MDA need to
take the importance of community engagement into
account.
Plans for the post-2007 period included dividing the
country into 4 implementation/evaluation units by div-
ision [27, 32]; the Northern Division was later further
subdivided further into two units. The WHO regional
meeting in 2008 [33] recommended that MDA continue
in Western, Northern, and Central Divisions, while
Eastern would pursue a strategy of test and treat for
positive cases. Directly observed treatment was intro-
duced in Northern Division. A revised health communi-
cation strategy would be developed and implemented,
and additional independent coverage surveys performed,
with the next C survey planned in 2010. The WHO re-
gional meeting in 2011 [34] noted that MDA was con-
ducted in all 4 implementation units in 2008–2009, after
which it stopped in Western Division. Central and
Eastern Divisions continued MDA in 2010 and 2011;
pre-TAS and TAS surveys were planned in Western
Division in 2011 and in Central/Eastern Divisions in
2012. At the time of the 2011 meeting, MDA continued
in Northern Division, while the test and treat program
continued in remote island sites in Eastern Division. A
renewed focus on identification of persons with morbid-
ity and provision of services including hydrocoele sur-
gery occurred after 2008 [34, 35].
Feedback regarding a national LF coordinator for Fiji
suggested that implementation of someone in the pos-
ition full time would have allowed for a more synchro-
nized program between divisions. However, funding for
this position was hard to secure and so there was a delay
in establishing a representative in this role. There were
issues with coordinating every island within the four di-
visions, and maintaining a consistent MDA availability
across the entire division was a challenge as was the
level of participation. Efforts intensified after 2007, but
continuing transmission led to more MDA rounds in
the face of continuing transmission, and the testing of
triple drug MDA in the Eastern Division in 2018 [37].
There are several other Polynesian countries and terri-
tories with day-biting Aedes vectors (Niue, Cook Islands,
Tonga, Wallis and Futuna) that have achieved validation
of elimination of LF as a public health problem, although
others are finding it difficult to reach the stop-MDA
thresholds or are facing resurgence (Samoa, American
Samoa, French Polynesia, Tuvalu) [10]. The reasons for
success or difficulty are varied: some countries are small
and relatively compact (Niue [38], Cook Islands [39]),
have consistent and effective program managers despite
being widely dispersed (Tonga [40]) or had relatively low
prevalence at the start of PacELF (Wallis and Futuna
[41]). Unlike some other countries in the region [42], the
four successful countries/territories did not stop MDA
until prevalence in all age groups was 1% or below, fol-
lowing PacELF guidelines [9]. Fiji’s large size and dis-
persed population together with lack of consistent
program management made it unable to reach the
needed MDA coverage levels between 2002 and 2006.
Therefore, Fiji’s decision to continue MDA after 2007
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with increased attention to monitoring, evaluation, com-
munication, and morbidity was a wise one.
Conclusions
During the years 1997 through 2007, Fiji dramatically re-
duced the overall prevalence of LF, particularly Mf
prevalence, especially in Western and Northern Divi-
sions. However, despite five rounds of MDA between
2002 and 2006 and large reduction in prevalence in all
ages, the threshold for stopping MDA was not reached.
The implementation of MDA and surveillance in con-
junction with supportive activities in Fiji was challenging
due to high starting prevalence, efficient mosquito vec-
tors, extreme geographical spread of the population, and
lack of consistent program management. The Fiji LF
program has learned from persistence of transmission
that has required adjustments and improvements to the
elimination strategy over time, including multiple add-
itional MDA rounds, application of better designed
coverage and prevalence surveys, repeated revisions of
implementation/evaluation units, improved communica-
tion strategies, attention to filariasis morbidity, and trials
of delivery and surveillance approaches as it continues
to pursue the goal of elimination of LF.
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